Definite | $10,000,000 | (Aug 22, 2025)
WALLROUND | $4,873,008 | (Aug 22, 2025)
Method AI | $20,000,000 | (Aug 22, 2025)
Certified by Founder
Lodge
Bryleos
start up
United States
- Johnson City, Tennessee
- 14/06/2023
- Seed
- $5,000,000
Early clinical stage therapeutics company developing BNAD101, a patent-pending oral composition of NAD+ clinically proven to increase intracellular NAD+. BNAD101 is a potential high-value medicine to treat challenging and costly neurological disorders.
In 2022, the Company completed its double-blind, placebo-controlled proof of concept study at the Institute of Systems Biology. The study of 60 healthy adults demonstrated BNAD101 had a 52% increase in intracellular NAD levels against placebo within just 5 days, effectively validating the potential of BNAD101 in treating not only chronic neurological conditions but conditions were swift response is critical.
Bryleos: More Life While Living
- Industry Biotechnology Research
- Website https://bryleos.com/
- LinkedIn https://www.linkedin.com/company/bryleos/
Therm | $3,600,000 | (Aug 22, 2025)
SugaROx | $1,341,635 | (Aug 22, 2025)
Molecular You | $5,000,000 | (Aug 22, 2025)
Verdata | $8,000,000 | (Aug 22, 2025)
Agenda Hero | $5,600,000 | (Aug 22, 2025)
The Better Meat Co. | $31,000,000 | (Aug 22, 2025)
CLIKA Inc. | Undisclosed Amount | (Aug 22, 2025)
Grid Aero | $6,000,000 | (Aug 22, 2025)
CVector | $1,500,000 | (Aug 22, 2025)